New antibody weapon targets Hard-to-Treat brain lymphoma
NCT ID NCT05485753
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 37 times
Summary
This early-stage study tests a new drug called GNC-038 in people with a type of brain lymphoma that has returned or not responded to treatment. The main goals are to find a safe dose and check for side effects. Only 7 participants are enrolled, so results will be very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.